JP2014502961A5 - - Google Patents

Download PDF

Info

Publication number
JP2014502961A5
JP2014502961A5 JP2013543601A JP2013543601A JP2014502961A5 JP 2014502961 A5 JP2014502961 A5 JP 2014502961A5 JP 2013543601 A JP2013543601 A JP 2013543601A JP 2013543601 A JP2013543601 A JP 2013543601A JP 2014502961 A5 JP2014502961 A5 JP 2014502961A5
Authority
JP
Japan
Prior art keywords
seq
composition
peptide
peptides
prostate cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013543601A
Other languages
English (en)
Japanese (ja)
Other versions
JP6032853B2 (ja
JP2014502961A (ja
Filing date
Publication date
Priority claimed from PCT/EP2010/069675 external-priority patent/WO2011073215A2/fr
Application filed filed Critical
Priority claimed from PCT/EP2011/070024 external-priority patent/WO2012079878A2/fr
Publication of JP2014502961A publication Critical patent/JP2014502961A/ja
Publication of JP2014502961A5 publication Critical patent/JP2014502961A5/ja
Application granted granted Critical
Publication of JP6032853B2 publication Critical patent/JP6032853B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013543601A 2010-12-14 2011-11-14 前立腺関連抗原分子由来hla結合ペプチドおよびその使用方法 Expired - Fee Related JP6032853B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2010/069675 WO2011073215A2 (fr) 2009-12-14 2010-12-14 Peptides se liant aux hla, dérivés de molécules antigéniques associées à la prostate, et leurs procédés d'utilisation
EPPCT/EP2010/069675 2010-12-14
PCT/EP2011/070024 WO2012079878A2 (fr) 2010-12-14 2011-11-14 Peptides se liant au hla dérivés de molécules antigéniques associées à la prostate et procédés d'utilisation associés

Publications (3)

Publication Number Publication Date
JP2014502961A JP2014502961A (ja) 2014-02-06
JP2014502961A5 true JP2014502961A5 (fr) 2014-12-25
JP6032853B2 JP6032853B2 (ja) 2016-11-30

Family

ID=44983532

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013543601A Expired - Fee Related JP6032853B2 (ja) 2010-12-14 2011-11-14 前立腺関連抗原分子由来hla結合ペプチドおよびその使用方法

Country Status (9)

Country Link
JP (1) JP6032853B2 (fr)
KR (1) KR20130126671A (fr)
CN (1) CN103547283A (fr)
AU (1) AU2011344652B2 (fr)
CA (1) CA2821582A1 (fr)
MX (1) MX2013006758A (fr)
NZ (1) NZ609916A (fr)
SG (1) SG191154A1 (fr)
WO (1) WO2012079878A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102013012432A1 (de) * 2013-07-29 2015-01-29 Eberhard Karls Universität Tübingen Medizinische Fakultät Immuntherapie von Prostatakrebs
CN106456784A (zh) * 2014-04-16 2017-02-22 拜康有限公司 包含摩尔过量的山梨醇的稳定蛋白质制剂
CA3172801A1 (fr) * 2015-06-12 2016-12-15 Lentigen Technology, Inc. Procede de traitement de cancer a l'aide de lymphocytes t genetiquement modifies
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
GB201521746D0 (en) * 2015-12-10 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
GB201602918D0 (en) * 2016-02-19 2016-04-06 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
KR102639592B1 (ko) 2016-12-08 2024-02-21 이매틱스 바이오테크놀로지스 게엠베하 짝짓기가 향상된 t 세포 수용체
CA3053133A1 (fr) * 2017-02-12 2018-08-16 Neon Therapeutics, Inc. Methodes et compositions reposant sur le hla et leurs utilisations
KR102215578B1 (ko) * 2019-03-28 2021-02-15 한국과학기술연구원 인간 백혈구 항원에 특이적으로 결합하는 펩타이드 및 이의 용도

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA725596A (en) 1960-08-26 1966-01-11 J. Wretlind Arvid Method of preparing intravenously injectable fat emulsions free from side reactions or complications
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP1244465A4 (fr) * 1999-12-21 2005-01-12 Epimmune Inc Induction de reponses immunitaires cellulaires aux antigenes du cancer de la prostate au moyen de compositions de peptides et d'acides nucleiques
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US20020081680A1 (en) * 2000-04-17 2002-06-27 Jiangchun Xu Compositions and methods for the therapy and diagnosis of prostate cancer
US7892559B2 (en) 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
US20030235533A1 (en) * 2002-02-19 2003-12-25 Idec Pharmaceuticals Corporation Prostate specific genes and the use thereof in design or therapeutics
AU2003256912A1 (en) * 2002-08-16 2004-03-03 Yeda Research And Development Co. Ltd. Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines
US20060205934A1 (en) * 2002-12-05 2006-09-14 Macina Roberto A Compositions, splice variants and methods relating to breast specific genes and proteins
WO2005033265A2 (fr) * 2003-04-25 2005-04-14 Epimmune Inc. Constructions multi-epitope optimisees et leurs utilisations
WO2006023598A2 (fr) * 2004-08-19 2006-03-02 University Of Maryland, Baltimore Peptides restreints par mhc classe ii derives d'antigenes specifiques a la prostate et leur utilisation dans des vaccins destines a traiter ou a prevenir le cancer de la prostate
DE602004019215D1 (de) 2004-10-02 2009-03-12 Immatics Biotechnologies Gmbh Immunogene T-Helfer Epitope von menschlichen Tumorantigenen und deren Verwendung in immunotherapeutischen Methoden
DK1806359T3 (da) 2005-09-05 2010-06-14 Immatics Biotechnologies Gmbh Tumorassocierede peptider, der bindes promiskuøst til Humant Leukocyt-Antigen (HLA) klasse II molekyler
ATE462442T1 (de) * 2008-04-30 2010-04-15 Immatics Biotechnologies Gmbh Neuartige formulierungen von tumor-assoziierten peptiden, welche an menschliche leukozytenantigene der klasse i oder ii für impfungen binden
NO2119726T3 (fr) * 2008-05-14 2015-05-23
EP2172211B1 (fr) * 2008-10-01 2014-12-03 Immatics Biotechnologies GmbH Composition de peptide associé aux tumeurs et vaccin anti-cancer associé pour le traitement de glioblastome (GBM) et autres cancers

Similar Documents

Publication Publication Date Title
JP2014502961A5 (fr)
PE20240645A1 (es) Peptido inmunogenico derivado de moleculas de antigenos leucocitarios humanos (hla) como biomarcador en la inmunoterapia de diversos tumores
AR121587A2 (es) Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer
EA201892021A1 (ru) Трансфицированные t-клетки и t-клеточные рецепторы для применения в иммунотерапии раковых заболеваний
EA201891759A1 (ru) Трансфицированные t-клетки и t-клеточные рецепторы для применения в иммунотерапии раковых заболеваний
EA201791150A1 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии гепатоклеточной карциномы (гкк) и других видов рака
UA103751C2 (ru) Иммуногенный пептид для иммунотерапии
JP2018510215A5 (fr)
NZ609916A (en) Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
MX2011007963A (es) Peptidos neil3 y vacunas que incluyen los mismos.
BR112012018457A2 (pt) peptídeos melk modificados e vacinas contendo os mesmos
RU2014109137A (ru) Пептиды mphosph1 и вакцины, включающие их
CA3033115A1 (fr) Nouveaux peptides et echafaudages destines a etre utilises en immunotherapie contre le carcinome a cellules squameuses de la tete et du cou et d'autres cancers
NZ601980A (en) Recombinant proteins for use in vaccine, antibodies against said proteins, and diagnostic and therapeutic methods including the same
JP2012526519A5 (fr)
EP3208334A3 (fr) Peptides cdc45l et vaccins les comportant
RU2011150283A (ru) Пептиды ттк и вакцины, их содержащие
EA201390811A1 (ru) Пептиды tomm34 и содержащие их вакцины
MX2020004757A (es) Nuevos peptidos y nueva combinacion de peptidos para el uso en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cancer.
BR112012014345A2 (pt) peptídeos tmem22 e vacinas incluindo os mesmos
MX2013004417A (es) Peptidos wdhd1 y vacunas que los incluyen.
NZ593200A (en) Peptide adjuvants
BR112013009276A2 (pt) peptídeos de c18orf54 e vacinas incluindo os mesmos
RU2013135148A (ru) Полиэпитопные иммуногенные полипептиды и способы их применения
AR122383A2 (es) Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer